Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 15/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827020 | 0.92 | NTRK1 (0.44) | NTRK1KDRRETEPHB2CLK2 | |
| SCHEMBL572717 | 0.91 | NTRK1 (0.43) | NTRK1KDRRETEPHB2CLK2 | |
| SCHEMBL574211 | 0.91 | NTRK1 (0.55) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL574065 | 0.90 | NTRK1 (0.54) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL574328 | 0.90 | NTRK1 (0.54) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL573043 | 0.90 | NTRK1 (0.48) | NTRK1KDRRETEPHB2CLK2 | |
| SCHEMBL574399 | 0.89 | NTRK1 (0.53) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL573446 | 0.89 | RIPK1 (0.42) | NTRK1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL573433 | 0.88 | KDR (0.52) | NTRK1KDRBRAF | |
| SCHEMBL827379 | 0.85 | NTRK1 (0.52) | NTRK1KDRRETEPHB2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | NTRK1 1105/4885KDR 2434/4885RET 190/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | NTRK1 211/4885KDR 239/4885RET 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.